Literature DB >> 2259879

B27+ disease versus B27- disease.

A Linssen1.   

Abstract

When studying heterogeneity of B27-positive disease versus B27-negative disease, very different patterns of disease associations but also a lot of similarities may be observed. In general, B27-positive disease has an earlier onset, a more severe and prolonged clinical course and is more often complicated by acute anterior uveitis and peripheral arthritis, whereas B27-negative disease is accompanied by psoriasis, inflammatory bowel disease and erythema nodosum in a higher percentage of the cases. Despite these differences, B27-positive disease may be completely undistinguishable from B27-negative disease in a number of individual cases. Family aggregation and male preponderance, however, are only seen in B27-positive disease. These observations may lead to the conclusion that HLA-B27 is probably not the only key to the pathogenesis of these diseases, but nevertheless an important genetic factor in disease expression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2259879

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  14 in total

1.  Sexual dimorphism, but not testosterone itself, is responsible for ankylosing enthesitis of the ankle in B10.BR (H-2k) male mice.

Authors:  J Capkova; P Ivanyi; Z Rehakova
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

2.  Non-HLA-B27 genetic factors in HLA-B27 associated diseases.

Authors:  T E Feltkamp
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 5 Initial diagnosis/referral strategy].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; A Heiligenhaus; U Pleyer; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; K-G Hermann; W-H Böhncke; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

4.  Solute carrier family 11 member A1 gene polymorphisms in reactive arthritis.

Authors:  Yi-Jing Chen; Chia-Hui Lin; Tsan-Teng Ou; Cheng-Chin Wu; Wen-Chan Tsai; Hong-Wen Liu; Jeng-Hsien Yen
Journal:  J Clin Immunol       Date:  2007-01-09       Impact factor: 8.317

Review 5.  Inflammatory conditions of the eye associated with rheumatic diseases.

Authors:  N A Afshari; M A Afshari; C S Foster
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 6.  Ankylosing Spondylitis: HLA-B*27-Positive Versus HLA-B*27-Negative Disease.

Authors:  Nurullah Akkoç; Handan Yarkan; Gökçe Kenar; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

7.  Comparison of the antibody responses to the 77 Klebsiella capsular types in ankylosing spondylitis and various rheumatic diseases.

Authors:  H Sahly; J Kekow; R Podschun; M Schaff; W L Gross; U Ullmann
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

8.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

Review 9.  Epidemiology of spondyloarthritis.

Authors:  Carmen Stolwijk; Annelies Boonen; Astrid van Tubergen; John D Reveille
Journal:  Rheum Dis Clin North Am       Date:  2012-08       Impact factor: 2.670

10.  Clinical features and prognosis of HLA-B27 positive and negative anterior uveitis in a Korean population.

Authors:  Sung Chul Park; Don-Il Ham
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.